The pharmacokinetics of dexrazoxane have been studied in advanced cancer patients with normal renal and hepatic function. The pharmacokinetics of dexrazoxane can be adequately described by a two-compartment open model with first-order elimination. Dexrazoxane has been administered as a 15 minute infusion over a dose range of 60 to 900 mg/m
2with 60 mg/m
2of doxorubicin, and at a fixed dose of 500 mg/m
2with 50 mg/m
2doxorubicin. The disposition kinetics of dexrazoxane are dose-independent, as shown by linear relationship between the area under plasma concentration-time curves and administered doses ranging from 60 to 900 mg/m
2. The mean peak plasma concentration of dexrazoxane was 36.5 mcg/mL at 15- minute after intravenous administration of 500 mg/m
2dose of dexrazoxane for injection over 15 to 30 minutes prior to the 50 mg/m
2doxorubicin dose.
The important pharmacokinetic parameters of dexrazoxane are summarized in Table 2:
Table 2: SUMMARY OF MEAN (%CV
a) DEXRAZOXANE PHARMACOKINETIC PARAMETERS AT A DOSAGE RATIO OF 10:1 OF DEXRAZOXANE FOR INJECTION: DOXORUBICIN
| Dose Doxorubicin (mg/m
2)
| Dose
Dexrazoxane for Injection
(mg/m
2)
| Number of Subjects | Elimination Half-Life (h) | Plasma Clearance (L/h/m
2)
| Renal Clearance (L/h/m
2)
| bVolume of Distribution
(L/m
2)
|
50
60
| 500
600
| 10
5
| 2.5(16)
2.1 (29)
| 7.88 (18)
6.25 (31)
| 3.35 (36)
-------
| 22.4 (22)
22.0 (55)
|
aCoefficient of variation
bSteady-state volume of distribution
Distribution
Following a rapid distributive phase (0.2 to 0.3 hours), dexrazoxane reaches post-distributive equilibrium within two to four hours. The estimated mean steady-state volume of distribution of dexrazoxane is 22.4 L/m
2after 500 mg/m
2of dexrazoxane for injection dose followed by 50 mg/m
2of doxorubicin, suggesting distribution throughout total body water (25 L/m
2).
In vitrostudies have shown that dexrazoxane is not bound to plasma proteins.
Metabolism
Qualitative metabolism studies with dexrazoxane have confirmed the presence of unchanged drug, a diacid-diamide cleavage product, and two monoacid-monoamide ring products in the urine of animals and man. The metabolite levels were not measured in the pharmacokinetic studies.
Excretion
Urinary excretion plays an important role in the elimination of dexrazoxane. Forty-two percent of a 500 mg/m
2dose of dexrazoxane for injection was excreted in the urine. Renal clearance averages 3.35 L/h/m
2after the 500 mg/m
2dexrazoxane for injection dose followed by 50 mg/m
2of doxorubicin.
Specific Populations
Pediatric
Pharmacokinetics following dexrazoxane for injection administration have not been evaluated in pediatric patients.
Effect of Renal Impairment
The pharmacokinetics of dexrazoxane were assessed following a single 15-minute IV infusion of 150 mg/m
2of dexrazoxane for injection. Dexrazoxane clearance was reduced in subjects with renal dysfunction. Compared with controls, the mean AUC
0-infvalue was two-fold greater in subjects with moderate (CL
CR30-50 mL/min) to severe (CL
CR<30 mL/min) renal dysfunction. Modeling demonstrated that equivalent exposure (AUC
-inf) could be achieved if dosing were reduced by 50% in subjects with creatinine clearance values <40 mL/min compared with control subjects (CL
CR>80 mL/min)
[see Use in Specific Populations (
8.6) and Dosage and Administration (
2.2)].
Effect of Hepatic Impairment
Pharmacokinetics following dexrazoxane for injection administration have not been evaluated in patients with hepatic impairment. The dexrazoxane for injection dose is dependent upon the dose of doxorubicin
[see Dosage and Administration (
2.2)].
Drug Interactions
There was no significant change in the pharmacokinetics of doxorubicin (50 mg/m
2) and its predominant metabolite, doxorubicinol, in the presence of dexrazoxane (500 mg/m
2) in a crossover study in cancer patients.